Detalhe da pesquisa
1.
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Eur Respir J
; 61(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229048
2.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Kidney Int
; 101(2): 403-413, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34560137
3.
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
Ann Rheum Dis
; 79(10): 1340-1348, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32699034
4.
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression.
Lupus
; 29(9): 1011-1020, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32571142
5.
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Mod Rheumatol
; 30(2): 313-320, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199180
6.
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Mod Rheumatol
; 29(3): 452-460, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29792370
7.
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Ann Rheum Dis
; 77(3): 355-363, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29295825
8.
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Arthritis Res Ther
; 24(1): 46, 2022 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172878
9.
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
RMD Open
; 8(1)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35428697
10.
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Arthritis Rheumatol
; 74(1): 112-123, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34164944
11.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken)
; 74(11): 1822-1828, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439360
12.
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
Lupus Sci Med
; 8(1)2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33568389
13.
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
RMD Open
; 7(2)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215703
14.
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
RMD Open
; 7(3)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531304
15.
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Lancet Rheumatol
; 3(2): e122-e130, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279368
16.
The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Arthritis Res Ther
; 22(1): 102, 2020 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32366280
17.
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
Lupus Sci Med
; 5(1): e000288, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30588323
18.
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Arthritis Rheumatol
; 69(5): 1016-1027, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28118533
19.
Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
J Med Econ
; 16(5): 667-77, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23425294
20.
Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.
Clin Ther
; 33(10): 1413-32, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21999885